12.00
12.00 (0%)
As of Feb 14, 2025
Forte Biosciences, Inc. [FBRX]
Source:
Company Overview
Forte Biosciences, Inc. and its subsidiaries is a clinical-stage biopharmaceutical company whose current lead product candidate is FB102. FB102 is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
| Country | United States |
| Headquarters | dallas, texas |
| Phone Number | ( 310 ) 618-6994 |
| Industry | manufacturing |
| CEO | Paul Wagner |
| Website | www.fortebiorx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-36.6 |
| Net Income | $-35.5 |
| Net Cash | $-14.9 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -70.6% |
| Profit as % of Stockholder Equity | -67.6% |
Management Effectiveness
| Return on Equity | -67.6% |
| Return on Assets | -57.6% |
| Turnover Ratio | |
| EBITA | $-36.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $61.6 |
| Total Liabilities | $9.1 |
| Operating Cash Flow | $-30.7 |
| Investing Cash Flow | $-36 |
| Financing Cash Flow | $51.9 |
